163 related articles for article (PubMed ID: 29615404)
61. Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.
Xu-Monette ZY; Li L; Byrd JC; Jabbar KJ; Manyam GC; Maria de Winde C; van den Brand M; Tzankov A; Visco C; Wang J; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Wang M; Hagemeister FB; Piris MA; Han van Krieken J; Medeiros LJ; Li Y; van Spriel AB; Young KH
Blood; 2016 Dec; 128(26):3083-3100. PubMed ID: 27760757
[TBL] [Abstract][Full Text] [Related]
62. Rational Targeting of Cellular Cholesterol in Diffuse Large B-Cell Lymphoma (DLBCL) Enabled by Functional Lipoprotein Nanoparticles: A Therapeutic Strategy Dependent on Cell of Origin.
Rink JS; Yang S; Cen O; Taxter T; McMahon KM; Misener S; Behdad A; Longnecker R; Gordon LI; Thaxton CS
Mol Pharm; 2017 Nov; 14(11):4042-4051. PubMed ID: 28933554
[TBL] [Abstract][Full Text] [Related]
63. DUSP4 deficiency caused by promoter hypermethylation drives JNK signaling and tumor cell survival in diffuse large B cell lymphoma.
Schmid CA; Robinson MD; Scheifinger NA; Müller S; Cogliatti S; Tzankov A; Müller A
J Exp Med; 2015 May; 212(5):775-92. PubMed ID: 25847947
[TBL] [Abstract][Full Text] [Related]
64. ApoA-I/SR-BI modulates S1P/S1PR2-mediated inflammation through the PI3K/Akt signaling pathway in HUVECs.
Ren K; Lu YJ; Mo ZC; -Liu X; Tang ZL; Jiang Y; Peng XS; Li L; Zhang QH; Yi GH
J Physiol Biochem; 2017 May; 73(2):287-296. PubMed ID: 28181168
[TBL] [Abstract][Full Text] [Related]
65. MYC Protein-positive Diffuse Large B-Cell Lymphoma Features an Activated B-Cell Receptor Signal Pathway.
Wang WG; Jiang XN; Liu ZB; Zhou XY; Li XQ
Am J Surg Pathol; 2017 Apr; 41(4):541-549. PubMed ID: 28291124
[TBL] [Abstract][Full Text] [Related]
66. Tumor cell-derived IL-10 promotes cell-autonomous growth and immune escape in diffuse large B-cell lymphoma.
Stirm K; Leary P; Bertram K; Núñez NG; Wüst D; Boudesco C; Verhoeyen E; Zenz T; Becher B; Menter T; Tzankov A; Müller A
Oncoimmunology; 2021; 10(1):2003533. PubMed ID: 34858727
[TBL] [Abstract][Full Text] [Related]
67. Aberrant SPOP-CHAF1A ubiquitination axis triggers tumor autophagy that endows a therapeutical vulnerability in diffuse large B cell lymphoma.
Yan W; Shi X; Wang H; Liao A; Yang W
J Transl Med; 2022 Jun; 20(1):296. PubMed ID: 35773729
[TBL] [Abstract][Full Text] [Related]
68. Selective delivery of T22-PE24-H6 to CXCR4
Falgàs A; Pallarès V; Serna N; Sánchez-García L; Sierra J; Gallardo A; Alba-Castellón L; Álamo P; Unzueta U; Villaverde A; Vázquez E; Mangues R; Casanova I
Theranostics; 2020; 10(12):5169-5180. PubMed ID: 32373205
[No Abstract] [Full Text] [Related]
69. Targeting of SMAD5 links microRNA-155 to the TGF-beta pathway and lymphomagenesis.
Rai D; Kim SW; McKeller MR; Dahia PL; Aguiar RC
Proc Natl Acad Sci U S A; 2010 Feb; 107(7):3111-6. PubMed ID: 20133617
[TBL] [Abstract][Full Text] [Related]
70. Evaluation of S1PR1, pSTAT3, S1PR2, FOXP1 Expression in Aggressive, Mature B Cell Lymphomas.
Al-Kawaaz M; Sanchez T; Kluk MJ
J Hematop; 2019 Jun; 12(2):57-65. PubMed ID: 31404445
[TBL] [Abstract][Full Text] [Related]
71. [Chlorpromazine hydrochloride plays a tumor suppressive role in diffuse large B lymphoma by promoting the expression of S1PR2].
Liang Z; Zang YQ; Lu Y; Dong QP; Dong KT; Zhou HF
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2021 Jun; 39(6):418-423. PubMed ID: 34218556
[No Abstract] [Full Text] [Related]
72. Tetraspanin CD37 protects against the development of B cell lymphoma.
de Winde CM; Veenbergen S; Young KH; Xu-Monette ZY; Wang XX; Xia Y; Jabbar KJ; van den Brand M; van der Schaaf A; Elfrink S; van Houdt IS; Gijbels MJ; van de Loo FA; Bennink MB; Hebeda KM; Groenen PJ; van Krieken JH; Figdor CG; van Spriel AB
J Clin Invest; 2016 Feb; 126(2):653-66. PubMed ID: 26784544
[TBL] [Abstract][Full Text] [Related]
73. Unveiling role of sphingosine-1-phosphate receptor 2 as a brake of epithelial stem cell proliferation and a tumor suppressor in colorectal cancer.
Petti L; Rizzo G; Rubbino F; Elangovan S; Colombo P; Restelli S; Piontini A; Arena V; Carvello M; Romano B; Cavalleri T; Anselmo A; Ungaro F; D'Alessio S; Spinelli A; Stifter S; Grizzi F; Sgambato A; Danese S; Laghi L; Malesci A; Vetrano S
J Exp Clin Cancer Res; 2020 Nov; 39(1):253. PubMed ID: 33225975
[TBL] [Abstract][Full Text] [Related]
74. Stress-induced premature senescence activated by the SENEX gene mediates apoptosis resistance of diffuse large B-cell lymphoma via promoting immunosuppressive cells and cytokines.
Wang J; Tao Q; Pan Y; Wanyan Z; Zhu F; Xu X; Wang H; Yi L; Zhou M; Zhai Z
Immun Inflamm Dis; 2020 Dec; 8(4):672-683. PubMed ID: 33015970
[TBL] [Abstract][Full Text] [Related]
75. CRISPR/Cas9-Mediated Foxp1 Silencing Restores Immune Surveillance in an Immunocompetent A20 Lymphoma Model.
Felce SL; Anderson AP; Maguire S; Gascoyne DM; Armstrong RN; Wong KK; Li D; Banham AH
Front Oncol; 2020; 10():448. PubMed ID: 32309216
[TBL] [Abstract][Full Text] [Related]
76. Regulation of normal B-cell differentiation and malignant B-cell survival by OCT2.
Hodson DJ; Shaffer AL; Xiao W; Wright GW; Schmitz R; Phelan JD; Yang Y; Webster DE; Rui L; Kohlhammer H; Nakagawa M; Waldmann TA; Staudt LM
Proc Natl Acad Sci U S A; 2016 Apr; 113(14):E2039-46. PubMed ID: 26993806
[TBL] [Abstract][Full Text] [Related]
77. Targetable vulnerability of deregulated FOXM1/PLK1 signaling axis in diffuse large B cell lymphoma.
Yu F; He H; Nastoupil LJ; Xu-Monette ZY; Pham K; Liang Y; Chen G; Fowler NH; Yin CC; Tan D; Yang Y; Hu S; Young KH; Pham LV; You MJ
Am J Cancer Res; 2022; 12(10):4666-4679. PubMed ID: 36381323
[TBL] [Abstract][Full Text] [Related]
78. FOXP1-GINS1 axis promotes DLBCL proliferation and directs doxorubicin resistance.
Chen Z; Wang T; Li C; Zhang W; Huang W; Xue J; Wang J; Li S
J Cancer; 2023; 14(12):2289-2300. PubMed ID: 37576391
[TBL] [Abstract][Full Text] [Related]
79. Inhibition of Sphingosine-1-Phosphate Receptor 2 by JTE013 Enhanced Alveolar Bone Regeneration by Promoting Angiogenesis.
Lory W; Wellslager B; Sun C; Yilmaz Ö; Yu H
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834810
[TBL] [Abstract][Full Text] [Related]
80. SMAD1 as a biomarker and potential therapeutic target in drug-resistant multiple myeloma.
Wu J; Zhang M; Faruq O; Zacksenhaus E; Chen W; Liu A; Chang H
Biomark Res; 2021 Jun; 9(1):48. PubMed ID: 34134766
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
